Results 171 to 180 of about 4,765 (219)
Some of the next articles are maybe not open access.
Bortezomib and Waldenstrom's macroglobulinemia
Expert Opinion on Pharmacotherapy, 2009Despite advances in therapy, Waldenstrom's macroglobulinemia (WM) remains incurable. Guidelines on therapeutic alternatives in WM recommended the use of alkylating agents, rituximab, nucleoside analogues and anthracyclins either in first line or at relapse and in combination in fit patients.
Laurent Pascal +2 more
exaly +3 more sources
Angiogenesis in Waldenstrom's macroglobulinemia
Seminars in Oncology, 2003Angiogenesis has been associated with disease progression and poor prognosis in several hematologic malignancies including multiple myeloma. In this article, we summarize the rationale for studying angiogenesis in plasma cell disorders including Waldenstrom's macroglobulinemia (WM). We also discuss the results of a study of angiogenesis in WM conducted
S Vincent, Rajkumar +2 more
openaire +2 more sources
Fludarabine in Waldenstrom's macroglobulinemia
Seminars in Oncology, 2003Waldenstrom's macroglobulinemia (WM), a rare B-cell malignancy, is incurable. Conventional treatment consists of alkylating agents (especially chlorambucil), with or without corticosteroids. Purine analogues such as fludarabine are also active. Response rates to first-line therapy range from 38% to 85%. Discrepancies in response rates between different
Véronique, Leblond, Sylvain, Choquet
openaire +2 more sources
Defining Waldenstrom's macroglobulinemia
Seminars in Oncology, 2003NEARLY 60 YEARS have passed since Jan Gosta Waldenstrom (Fig 1) first described two patients with oronasal bleeding, lymphadenopathy, anemia and thrombocytopenia, elevated erythrocyte sedimentation rate, high serum viscosity level, normal bone radiographs, and bone marrow demonstrating predominately lymphoid cells.1 These seminal observations provided ...
Steven P, Treon +2 more
openaire +2 more sources
Fludarabine in Waldenstrom’s macroglobulinemia
Expert Review of Hematology, 2013Waldenstrom's macroglobulinemia is a rare chronic lymphoproliferative disorder. Treatment is usually based on nucleoside analogues, alkylators, bortezomib and monoclonal antibodies, alone or in combination. Fludarabine is a fluorinated purine analogue effective in chronic lymphoproliferative disorders.
Laetitia, Souchet-Compain +3 more
openaire +2 more sources
Asymptomatic Waldenstrom's macroglobulinemia
Seminars in Oncology, 2003A study was undertaken to evaluate the frequency and natural history of disease in patients with asymptomatic Waldenstrom's macroglobulinemia (WM). Among 132 consecutive, newly diagnosed patients with monoclonal IgM, 82 (27%) had symptomatic WM indicated by anemia, lymphadenopathy, or splenomegaly.
R, Alexanian +4 more
openaire +2 more sources
Radioimmunotherapy for Waldenstrom's macroglobulinemia
Seminars in Oncology, 2003Radioimmunotherapy targeting CD20 is a promising novel treatment for lymphoma. Prior trials have established the safe dose of Zevalin ((90)Y-ibritumomab tiuxetan; IDEC Pharmaceuticals) for patients with no more than 25% bone marrow (BM) involvement. Zevalin is expected to be an effective treatment for WM; however, the safe dose has not been defined.
openaire +2 more sources
, 2001 Disease Waldenstrom's macroglobulinemia (corresponding to lymphoplasmacytoid lymphoma / Immunocytoma in the REAL and WHO classification) Phenotype / cell stem origin Stem cell origin: Post-germinal centre IgM-bearing memory B-cell. Phenotype: CD19+; CD20+; CD22+; FMC7+; CD38+; cytoplasmic IgM bright+; CD5-; CD23-; CD10-.
CUNEO, Antonio
openaire +2 more sources
Waldenstrom's macroglobulinemia.
The Journal of the Association of Physicians of India, 2005Waldenstrom's macroglobulinemia is an uncommon lymphoplasmacytic lymphoma presenting with hyperviscocity and autoimmune phenomenon. Disease is characterized by bone marrow infiltration by lymphoplasmacytic cells and raised IgM. Bone marrow morphology and immunohistochemistry is important for diagnosis.
N, Singhal +3 more
openaire +1 more source